Joshua Fitch, Senior Editor

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

According to the American Academy of Pediatrics (AAP), it is recommended that 45% to 65% of total daily calories come from carbohydrates, though very low-carbohydrate diets allow for 20 to 50 grams per day.

Lawrence Eichenfield, MD, reacts to the FDA's acceptance of a supplemental New Drug Application for roflumilast cream 0.15% to treat atopic dermatitis (AD) in patients aged 6 years and older.

The reaction, called Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), can start as a rash but can progress quickly, potentially resulting in injury to internal organs, hospitalization, and death. 

The FDA has accepted a supplemental New Drug Application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in children aged 6 years and up.

Yamo Pharmaceuticals has initiated a phase 3 readiness program for L1-79, following the enrollment of its final patient in a phase 2 study evaluating the autism spectrum disorder (ASD) treatment for patients aged 2 to 21 years.

The FDA granted Priority Review to pz-cel following a phase 1/2 and a pivotal phase 3 study in which the treatment for recessive dystrophic epidermolysis bullosa (RDEB) demonstrated wound healing and pain reduction.

The 2022-2023 influenza season was the fourth season to be classified as high severity since the 2009 influenza A(H1N1) pandemic. 

Understanding the knowledge about the structure of the family and its respective support system can play a role in determining and recognizing each family’s needs.

Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.

Once a food is accepted, similarly colored, textured, or flavored foods can be used in addition, expanding the number of items the child might eat.

Studies have shown that gratitude has led to improved sleep quality and has decreased symptoms of unexplained aches and pains, according to healthychildren.org.

The Fast Track Designation follows the recent announcement of phase 1/2 data from the Harmony trial.

The warning letters issued to 7 manufacturers are part of a larger, on-going effort by the FDA to address manufacturing, distribution, and sale of illegal and unauthorized e-cigarettes.

Overall, the study authors concluded that the immunogenicity of QIV and TIV was similar for common influenza ingredients for children aged 6 to 35 months.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The US approval makes VLA1553 (Ixchiq; Valneva) the world’s first licensed chikungunya vaccine.

A total of 3761 cases of congenital syphilis were reported to the CDC in 2022, with the lack of timely testing and adequate treatment contributing to 88% of these cases.

The study authors sought to compare pain scores over 2 years in 3 treatment strategies in non-systemic JIA patients who were treated to target aimed at inactive disease, and to determine the effect of inactive disease and time to inactive disease on pain.

In a systematic and meta-analysis review of cohort studies that featured nearly 1.7 million individuals, study authors concluded that there is an association between high body mass index (BMI) and an increased risk of incident type 1 diabetes (T1D).

Ustekinumab-auub is approved to treat indications that are currently approved for ustekinumab, including moderate to severe plaque psoriasis (candidates for phototherapy or systemic therapy) and for those with active psoriatic arthritis, aged 6 years and older.

The FDA was made aware some health care providers had administered the full single dose vial of the vaccine, which contains “notably more” volume than the 0.25 mL volume indicated for children aged 6 months to 11 years.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Take a look back at some of the top-performing stories from Contemporary Pediatrics with this review article. Stories featured in this article are re-capped and directly link to our most-viewed articles from August through October 2023.

For the first time since 2001 to 2002, a year-to-year increase of the infant mortality rate was observed in the United States from 2021 to 2022. The provisional 20,538 infant deaths reported in 2022 were a 3% increase compared to 2021.

Longer-term data was recently released for dupilumab as a treatment for eosinophilic esophagitis (EoE) in children aged 1 to 11 years, demonstrating a similar safety and efficacy profile for up to 1 year of treatment. A supplemental Biologic License Application was accepted by the FDA in September 2023 with a Priority Review designation.

A usability study demonstrated that individuals older than 18 years could self-administer the intranasal treatment or administer it to eligible patients aged 2 to 49 years, when given instructions and no additional guidance.

A child with profound genetic hearing loss was dosed with an investigational otoferlin gene therapy (DB-OTO), the first patient dosed in a phase 1/2 trial evaluating the treatment. The child experienced improved auditory response at week 6 with no concerning safety signals.

Vamorolone, oral suspension 40 mg / ml, has been approved by the FDA to treat Duchenne muscular dystrophy (DMD) in patients aged 2 years and up, according to Santhera Pharmaceuticals.

In this interview with Contemporary Pediatrics®, Lauren Lanzon, MSW, MA, BCBA, clinical trainer, Carolina Behavioral Innovations, explains how technology and software is helping families following an autism diagnosis in their child.